Rationale for use mefloquine for COVID-19 treatment
https://doi.org/10.37489/2588-0519-2020-S4-103-105
Abstract
Currently, the use of mefloquine in patients with COVID-19 does not have sufficient scientific justification and, given the unfavorable efficacy and safety profile, cannot be considered for routine use in clinical practice.
About the Authors
V. A. Otdelenov
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Otdelenov Vitaly A. – Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8357-5770
Moscow
K. B. Mirzaev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Mirzaev Karin B. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8308-7599
Moscow
A. V. Dmitriev
Institute of Biomedical Chemistry
Russian Federation
Russian Federation
Dmitriev Alexander V. – Candidate of Biology Sciences, Department of bioinformatics
Moscow
V. V. Poroikov
Institute of Biomedical Chemistry
Russian Federation
Russian Federation
Poroikov Vladimir V. – Candidate of physical and mathematical Sciences, Doctor of Biology Sciences, Professor, Corresponding Member RAS, Head of the bioinformatics Department. SPIN code: 8272-7797
Moscow
D. A. Sychev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head. Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556
Moscow
References
1. Drugbank.ca — Mefloquine [Internet]. [cited 2020 September 14]; Available from: https://www.drugbank.ca/drugs/DB00358
2. Wong W et al. Mefloquine targets the Plasmodium falciparum 80S ribosome to inhibit protein synthesis. Nat Microbiol. 2017 Mar 13;2:17031. DOI: 10.1038/nmicrobiol.2017.31
3. The state register of medicinal products. Mefloquine. Instructions for medical use. (In Russ). Доступно по: https://clck.ru/RCnSv Ссылка активна на 14.09.2020
4. Sachdeva C et al. In silico Potential of Approved Antimalarial Drugs for Repurposing Against COVID-19. OMICS. 2020 Jul 30. DOI: 10.1089/omi.2020.0071
5. Temporary guidelines of the Ministry of health of the Russian Federation for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19), version 8 of 03.09.2020. (In Russ). Доступно по: https://clck.ru/RCqBr Ссылка активна на 14.09.2020
6. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines NIH [Internet]. [cited 2020 September 14]; Available from: https://www.covid19treatmentguidelines.nih.gov/
7. National COVID-19 Clinical Evidence Taskforce [Internet]. [cited 2020 September 14]; Available from: https://covid19evidence.net.au
8. UW Medicine COVID-19 Resource Site [Internet]. [cited 2020 September 14]; University of Washington. 2020. Available from: https://covid-19.uwmedicine.org/Pages/default.aspx
9. Brigham and Women’s Hospital COVID-19 Clinical Guidelines [Internet]. [cited 2020 September 14]; Available from: https://covidprotocols.org/
10. State register of medicines. Register of permitted clinical trials. Mefloquine. (In Russ). Доступно по: https://grls.rosminzdrav.ru/CIPermitionReg.aspx Ссылка активна на 14.09.2020
11. FMBA of Russia: proven antiviral activity of Mefloquine against the pathogen COVID-19. (In Russ). Доступно по: https://fmba.gov.ru/press-tsentr/novosti/detail/?ELEMENT_ID=38239 Ссылка активна на 14.09.2020
12. State register of medicines. Registration certificate. Mefloquine. (In Russ).]. Доступно по: https://clck.ru/RCquE Ссылка активна на 14.09.2020
13. Dmitriev A, Filimonov D, Lagunin A et al. Prediction of severity of drug-drug interactions caused by enzyme inhibition and activation. Molecules. 2019 Oct 31;24(21):3955. DOI: 10.3390/molecules24213955
Review
For citations:
Otdelenov V.A., Mirzaev K.B., Dmitriev A.V., Poroikov V.V., Sychev D.A. Rationale for use mefloquine for COVID-19 treatment. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020;(4S):103-105. (In Russ.) https://doi.org/10.37489/2588-0519-2020-S4-103-105
Views:
1062
Email this article 